Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer
This purpose of this study is to evaluate the role of gemcitabine and docetaxel, a well tolerated chemotherapy regimen in the treatment of advanced non-small cell lung cancer (NSCLC), in combination with a novel agent cetuximab.
Lung Cancer
DRUG: Gemcitabine|DRUG: Docetaxel|DRUG: Cetuximab
Overall Clinical Response Rate, Overall response rate was defined as the proportion of treated patients whose best response was a complete or partial response after completing at least two courses of treatment., 18 months
Progression Free Survival (PFS), Progression free survival was defined as the interval between the start date of treatment and the date of occurrence of progressive disase or death from any cause., 18 months|Response Duration, The Response Duration was calculated from time of initial measured response to date of first observation of progressive disease., 18 months
Upon determination of eligibility all patients will receive:

* Docetaxel + Gemcitabine + Cetuximab